QIAGEN NV Stock News

Qiagen N.V. (NYSE:QGEN ) Q3 2024 Earnings Conference Call November 7, 2024 9:30 AM ET Company Participants John Gilardi - VP, Head of Corporate Communications and IR Thierry Bernard - CEO Roland Sackers - CFO Conference Call Participants Patrick Donnelly - Citi Odysseas Manesiotis - Berenberg Matt Sykes - Goldman Sachs Doug Schenkel - Wolfe Research Aisyah Noor - Morgan Stanley Michael Ryskin -...

Qiagen reported a rise in third-quarter revenue on Wednesday, owing to strong sales of its diagnostic devices.

Der Labordienstleister Qiagen NL0012169213 hat im vergangenen Quartal von einer anziehenden Nachfrage nach Diagnostiklösungen profitiert und seinen Umsatz überraschend stark gesteigert.

QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat‑Dx tests developed specifically for the U.S. // QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastrointestinal and central nervous system infections –...

QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions // With the new test and the 21-target QIAstat-Dx Respiratory Panel Plus, clinicians can fine-tune their diagnostic approach for individual patients, promoting better diagnostic stewardship // FDA decision marks third positive U.S. r...

Portfolio expansion reinforces QIAGEN's leadership in automated solutions for non-invasive liquid biopsy applications combined with complete workflows // New ccfDNA Kit upgrade with urine protocol for use on EZ1 and 2 instruments designed to enhance liquid biopsy workflows for cancer research // New QIAsymphony DSP Circulating DNA and Maxi Kits deliver high-quality cfDNA for use in downstream a...

Venlo, The Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the third quarter 2024.

QIAGEN's leading tuberculosis blood test QuantiFERON®-TB Gold Plus remains crucial for detection of latent tuberculosis infection, aiding in breaking the cycle of disease transmission // Over 35 top tuberculosis experts to discuss critical topics such as advancements in diagnostics and new treatment strategies // CPD- and CME-accredited event highlights the need for renewed global efforts for t...